#United States #gene therapy #Boulder #KROMATID #Matthew Hemstreet

KROMATID Welcomes New Leadership Under Matthew Hemstreet

KROMATID, a frontrunner in the domain of structural genomic integrity for cell and gene therapy, has formally appointed Matthew Hemstreet as its new Chief Executive Officer (CEO). This strategic decision comes at a crucial time as the company looks to solidify its market leadership. Hemstreet succeeds Terry Opgenorth, who served as the Interim CEO during a transformative phase of the company.

During his tenure, Opgenorth successfully navigated KROMATID through significant strategic changes, enhancing its focus on commercial operations and laying a robust foundation for sustainable growth. David Brunel, President of the Board of Directors, acknowledged Opgenorth's vital role in steering the company towards its next growth chapter, stating, "Terry was instrumental in helping position KROMATID for its next stage of growth."

Matthew Hemstreet's appointment as CEO is a testament to his deep understanding of the company and the industry at large. Since joining KROMATID in 2024 as Vice President of Global Marketing, Hemstreet has significantly contributed to the company’s strategic and operational evolution. With over ten years of leadership experience in global marketing, product management, and commercial strategy from renowned companies such as Terumo Blood and Cell Technologies and Medtronic, he is well-equipped to lead KROMATID into the future.

Under Hemstreet's leadership, KROMATID aims to build on the progress made so far by:

• - Expanding Global Presence: A key objective is enhancing KROMATID’s footprint in the global cell and gene therapy market, ensuring that the company remains at the forefront of innovation.
• - Fostering Strategic Partnerships: Strengthening collaborations with pharmaceutical giants, biotechnology innovators, CDMOs, and academic institutions will be crucial in maximizing KROMATID’s technological advantages.
• - Advancing Product Innovation: The acceleration of adoption for the KROMASURE™ genomic integrity platform and introducing new product innovations will support the company’s growth strategy.
• - Setting Industry Standards: KROMATID is poised to establish itself as the benchmark for genomic integrity assessment in advanced cellular therapies, providing developers with critical insights needed for effective product development.

Expressing his enthusiasm for the new role, Hemstreet noted, “I am honored to step into this role. The demand for deeper genomic integrity insights has never been greater. KROMATID is uniquely positioned to help developers of advanced therapies better understand, characterize, and de-risk their products.”

As he leads KROMATID into its next chapter, Hemstreet's vision is clear: to scale the company's impact, broaden its capabilities, and establish genomic integrity as a fundamental quality metric across the industry.

The Board of Directors extends thanks to Terry Opgenorth for his exemplary leadership during an interim period marked by significant transformations. Opgenorth remains a valued member of the Board, offering his experience and support as Hemstreet guides KROMATID through this ambitious phase of innovation and growth.

About KROMATID

KROMATID stands at the pinnacle of genomic structural analysis for cell and gene therapy developers, offering unmatched clarity into chromosomal integrity. By fusing proprietary imaging solutions with advanced bioinformatics, KROMATID enables accurate detection of structural variations, empowering developers to confidently navigate their therapeutic innovations from initial discovery all the way through to regulatory approval. For further details, visit www.kromatid.com.